logo-loader

ArQule, Inc. and Daiichi Sankyo's tivantinib trial to continue

Last updated: 11:49 22 Mar 2016 EDT, First published: 07:49 22 Mar 2016 EDT

cancercell_56f169cab47b9
Liver cancer is the sixth most common cancer globally

ArQule, Inc. (NASDAQ:ARQL)  and Daiichi Sankyo announced on Tuesday that the METIV-HCC study will continue to its final analysis.

METIV-HCC is a trial to evaluate tivantinib - an oral inhibitor of c-Met that binds to the protein and disrupts pathways, potentially causing cell death in tumor cells.

The study is measuring its effectiveness in patients with inoperable liver cancer (Hepatocellular Carcinoma or HCC) versus the current industry standard of care.

The trial is biomarker-selected, double-blind and placebo-controlled, and was approved by the independent data monitoring committee (DMC) after it conducted its planned interim assessment.

The mid-point analysis was required after 60% of the target number of milestones had been passed.

The METIV-HCC trial completed patient accrual in December 2015 with more than 300 patients with MET-high HCC enrolled.

ArQule and Daiichi Sankyo have been partners on the project since 2008, when they signed a licensing, co-development and co-commercialization agreement.

Liver cancer is the sixth most common cancer globally and is the second most common cause of cancer-related death.

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

6 hours, 58 minutes ago